Evidence map›Paper›PMID 38256885›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Surgical Primary Tumor Resection Reduces Accumulation of CD11b

Michael Donkor, Jamie Y Choe, Danielle Marie Reid, Hope K Fiadjoe, Byron Quinn, Amalendu Ranjan, Mark Pulse, Pankaj Chaudhary, Riyaz Basha, Harlan P Jones

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michael DonkorDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-5488-0328
Jamie Y ChoeDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-7803-5962
Danielle Marie ReidDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-3316-9115
Hope K FiadjoeDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.ORCID 0009-0002-2593-8129
Byron QuinnDepartment of Biology, Langston University, Langston, OK 73050, USA.
Amalendu RanjanDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.
Mark PulseDepartment of Pharmaceutical Sciences, UNT Health Science Center, Fort Worth, TX 76107, USA.
Pankaj ChaudharyDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.
Riyaz BashaDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.
Harlan P JonesDepartment of Microbiology, Immunology and Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA.
University of North Texas · USLangston University · US

Funding

Texas Minority Health, Research and Outreach (MiHERO)S21MD012472 · NIMHD · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JAMBOOR K. VISHWANATHA · 2017 to 2026
$18.0M
UNT Health Science Center IMSDR25GM125587 · NIGMS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI JONES, HARLAN PIERRE · 2018 to 2022
$1.4M
2/2 Pilot Project 2: Langston University-UNTHSC Partnership for Cancer Research and EducationP20CA233355 · NCI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI BASHA, RIYAZ · 2018 to 2021
$1.0M
Summer Undergraduate Research Internship ProgramR25DA043225 · NIDA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI Harlan Pierre Jones · 2018 to 2026
$927k
2/2 Pilot Project 2: Langston University-UNTHSC Partnership for Cancer Research and EducationP20CA233391 · NCI · LANGSTON UNIVERSITY · PI QUINN, BYRON N · 2018 to 2021
$777k
NCI NIH HHS P20 CA233355NCI NIH HHS P20 CA233391NIDA NIH HHS 5 R25 DA043225-04NIDA NIH HHS R25 DA043225NIGMS NIH HHS R25 GM125587NIH HHS 1 P20 CA233355-01NIMHD NIH HHS 5S21MD012472-05NIMHD NIH HHS S21 MD012472
6 · The paper itself

Abstract

A hallmark of effective cancer treatment is the prevention of tumor reoccurrence and metastasis to distal organs, which are responsible for most cancer deaths. However, primary tumor resection is expected to be curative as most solid tumors have been shown both experimentally and clinically to accelerate metastasis to distal organs including the lungs. In this study, we evaluated the efficacy of our engineered nasal nano-vaccine (CpG-NP-Tag) in reducing accelerated lung metastasis resulting from primary tumor resection. Cytosine-phosphate-guanine oligonucleotide [CpG ODN]-conjugated nanoparticle [NP] encapsulating tumor antigen [Tag] (CpG-NP-Tag) was manufactured and tested in vivo using a syngeneic mouse mammary tumor model following intranasal delivery. We found that our nasal nano-vaccine (CpG-NP-Tag), compared to control NPs administered after primary mammary tumor resection, significantly reduced lung metastasis in female BALB/c mice subjected to surgery (surgery mice). An evaluation of vaccine efficacy in both surgery and non-surgery mice revealed that primary tumor resection reduces CD11b

Indexed as

immune responseintranasal vaccinationlung metastasisMDSCsnanoparticles

Identifiers

PMID38256885
PMCPMC10821475
OpenAlexW4390347559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.